Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TEMODAR
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
- A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
- Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
- Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- Surgical Pembro +/- Olaparib w TMZ for rGBM
- Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
- Chlorpromazine and Standard of Care in Glioblastoma
- Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study
- Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- Preoperative Radiosurgery for the Treatment of High Grade Glioma, The NeoGlioma Study
- Temozolomide and Atezolizumab as Second Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
- Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
- Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
- Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
- Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
- Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
- A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- NG101m Adjuvant Therapy in Glioblastoma Patients
- Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 in Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
- Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
- Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
- A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
- Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
- Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
- 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
- A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
- Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
- Hyperpolarized Imaging in Diagnosing Participants With Glioma
- Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
- Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
- DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
- A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
- Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
- Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
- A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
- SGT-53 in Children With Recurrent or Progressive CNS Malignancies
- Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
- Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
- Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma
- Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
- Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
- Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
- Irinotecan and Temozolomide for Ewing Sarcoma
- Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
- Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
- Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma
- Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
- Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
- Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
- HUMC 1612: Optune NovoTTF-200A System
- Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
- Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
- Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
- Temozolomide Chronotherapy for High Grade Glioma
- Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
- An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
- Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
- Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
- Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
- Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
- Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
- Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
- Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
- Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
- Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
- DC Migration Study for Newly-Diagnosed GBM
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
- Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
- Image-derived Prediction of Response to Chemo-radiation in Glioblastoma
- A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
- Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
- IDH1 Peptide Vaccine for Recurrent Grade II Glioma
- Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
- Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
- Preoperative Chemoradiation for Glioblastoma
- Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
- MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
- Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
- PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
- 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
- Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
- Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
- FMISO-PET in Brain Tumors and SCS Effect
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
- Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
- A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
- Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
- MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
- A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
- A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
- A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
- Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
- Bevacizumab Beyond Progression (BBP)
- Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
- Study of MLN8237 in Combination With Irinotecan and Temozolomide
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- Doxycycline, Temozolomide and Ipilimumab in Melanoma
- Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
- Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
- Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
- Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
- Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
- Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
- IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
- Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
- Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
- Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
- Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
- Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
- Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
- Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
- Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
- ABT-888 and Temozolomide for Liver Cancer
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
- To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
- Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
- Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
- Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
- Bevacizumab in Recurrent Grade II and III Glioma
- Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
- Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
- Veliparib and Temozolomide in Treating Patients With Acute Leukemia
- Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
- RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
- Ipilimumab + Temozolomide in Metastatic Melanoma
- Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
- Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastom
- Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
- Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
- A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
- Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
- Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
- A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
- Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
- Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment
- Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
- Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
- Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
- Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
- Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
- Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
- ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
- Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
- A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
- Sorafenib in Newly Diagnosed High Grade Glioma
- Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
- Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas
- Capecitabine and Temozolomide for Neuroendocrine Cancers
- Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
- Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
- A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
- A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma
- A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
- CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
- A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
- Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
- Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
- Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
- Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
- Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
- Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
- Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
- A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
- Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
- O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
- Study of Temzolomide and Gleevec in Advanced Melanoma
- Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Dose-Intense Temozolomide in Recurrent Glioblastoma
- Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
- Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
- Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
- Phase III Trial of Anaplastic Glioma Without 1p/19q LOH
- Temozolomide in Treating Patients With Recurrent High-Grade Glioma
- Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
- Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
- Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
- Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
- PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
- Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
- Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
- Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
- Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
- Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
- Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
- RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
- Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
- Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
- Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
- Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
- Taxotere/Temodar/Cisplatin Study in Melanoma Patients
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
- Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
- VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
- DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
- Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM
- Biochemotherapy With Temozolomide for Metastatic Melanoma
- 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
- Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
- Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
- Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
- Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
- Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
- O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
- Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
- Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
- Abraxane and Temodar Plus Genasense in Advanced Melanoma
- Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
- A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
- Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
- Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
- Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
- Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Temozolomide in Treating Patients With Low-Grade Glioma
- Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
- Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Temodar and Sutent as Therapy for Melanoma
- Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
- Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
- Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
- O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
- Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
- Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
- Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
- Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
- Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
- Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
- Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
- Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
- Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
- Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
- Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
- Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
- Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
- Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
- Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
- Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
- Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
- Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
- Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
- Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
- Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
- Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
- Temozolomide in Treating Patients With Brain Metastases
- Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
- Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
- Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
Clinical trials list
click for details